Charles J. Schneider

Oncology

3400 Civic Center Boulevard
West Pavilion, 2nd Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: April 30, 2026

A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer.

A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer.

Journal: Cancer

Published: February 20, 2025

A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.

A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.

Journal: Targeted oncology

Published: February 03, 2025

NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.

NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: August 16, 2024

Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 11, 2024

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.

Journal: Nature communications

Published: December 05, 2023

Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study.

Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study.

Journal: Cardiovascular and interventional radiology

Published: August 04, 2023

Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 12, 2023

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 16, 2023

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.

Journal: British journal of cancer

Published: December 12, 2022

Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: October 14, 2022

Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.

Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.

Journal: JCO precision oncology

Published: August 08, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026